Lantheus Holdings develops and commercializes diagnostic imaging agents and radiopharmaceuticals used in nuclear medicine and ultrasound. Flagship products include PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, and DEFINITY, an ultrasound contrast agent for cardiac imaging. The company serves hospitals, imaging centers, and oncology practices with products that support disease detection, staging, and treatment decision-making.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 378.1 | — | 78.8 | — |
| Q3 2025 | 384 | — | 27.8 | — |
| Q4 2025 | 406.8 | — | 54.1 | — |
| Q1 2026 | 377.3 | — | 118.4 | — |
| Q2 2026 | 388.2 | 2.7% | 75 | -4.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Amdocs Limited (DOX), Plains GP Holdings, L.P. (PAGP), Powell Industries, Inc. (POWL), The Trade Desk, Inc. (TTD), Qualys, Inc. (QLYS), Cipher Digital Inc. (CIFR)